Deciphering the molecular basis of memory failure in Alzheimer's disease

Neuron

Volumn 44, Issue 1, 2004, Pages 181-193

  Walsh, Dominic M ^a,b   Selkoe, Dennis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; COGNITION; CORRELATION ANALYSIS; HUMAN; LEARNING; LONG TERM POTENTIATION; MEMORY; MEMORY DISORDER; NERVE CELL NETWORK; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; HUMANS; MEMORY DISORDERS; SYNAPSES;

EID: 5344277556     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2004.09.010     Document Type: Review

References (152)

1. Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde. Centralblatt fur Nervenheilkunde und Psychiatrie. 30:1907;177-179
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919
3. Bertoni-Freddari C., Fattoretti P., Casoli T., Caselli U., Meier-Ruge W. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Anal. Quant. Cytol. Histol. 18:1996;209-213
4. Bertoni-Freddari C., Fattoretti P., Meier-Ruge W., Ulrich J. Computer-assisted morphometry of synaptic plasticity during aging and dementia. Pathol. Res. Pract. 185:1989;799-802
5. Bitan G., Kirkitadze M.D., Lomakin A., Vollers S.S., Benedek G.B., Teplow D.B. Amyloid β-protein (Aβ) assembly. Aβ40 and Aβ42 oligomerize through distinct pathways Proc. Natl. Acad. Sci. USA. 100:2003;330-335
6. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013
7. Braak H., Braak E. Evolution of neuronal changes in the course of Alzheimers disease. J. Neural. Transm. Suppl. 53:1998;127-140
8. Braak E., Braak H., Mandelkow E.W. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. (Berl). 87:1994;554-567
9. Buckner R.L. Memory and executive function in aging and AD. Multiple factors that cause decline and reserve factors that compensate Neuron. 44:2004;195-208., this issue
10. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267:1992;546-554
11. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchlerpierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature. 395:1998;755-756
12. Chang W.P., Koelsch G., Wong S., Downs D., Da H., Weerasena V., Gordon B., Devasamudram T., Bilcer G., Ghosh A.K., Tang J. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J. Neurochem. 89:2004;1409-1416
13. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:1999;271-276
14. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979
15. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 3:1997;67-72
16. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid β-protein specifically disrupt the memory of learned behavior. Nat. Neurosci. in press:2004
17. Clements A., Walsh D.M., Williams C.H., Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid b/A4 peptide. Neurosci. Lett. 161:1993;17-20
18. Coleman P.D., Yao P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging. 24:2003;1023-1027
19. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C. Jr., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923
20. Cras P., van Harskamp F., van Duijn C., Hendriks L., Stefanko S.Z., Hofman A., Kros J.M., Ceuterick C., van Broeckhoven C., Martin J.J. Presenile Alzheimer dementia characterized by amyloid angiopathy and a large amyloid core type of senile plaques in the APP 692AlaGly mutation. Acta Neuropathol. (Berl.). 96:1998;253-260
21. Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 78:1987;151-164
22. De Jonghe C., Zehr C., Yager D., Prada C.M., Younkin S., Hendriks L., Van Broeckhoven C., Eckman C.B. Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. Neurobiol. Dis. 5:1998;281-286
23. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease. correlation with cognitive severity Ann. Neurol. 27:1990;457-464
24. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and Clusterin cooperatively suppress Abeta levels and deposition. Evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 41:2004;193-202
25. Dewachter I., Reverse D., Caluwaerts N., Ris L., Kuiperi C., Van Den Haute C., Spittaels K., Umans L., Serneels L., Thiry E., et al. Neuronal deficiency of Presenilin 1 inhibits Amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of Amyloid precursor protein [V717I] transgenic mice. J. Neurosci. 22:2002;3445-3453
26. Dickey C.A., Loring J.F., Montgomery J., Gordon M.N., Eastman P.S., Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J. Neurosci. 23:2003;5219-5226
27. Dickey C.A., Gordon M.N., Mason J.E., Wilson N.J., Diamond D.M., Guzowski J.F., Morgan D. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J. Neurochem. 88:2004;434-442
28. Dickson D.W. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56:1997;321-339
29. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-457
30. Drake J., Link C.D., Butterfield D.A. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol. Aging. 24:2003;415-420
31. Dudai Y. Molecular bases of long-term memories. a question of persistence Curr. Opin. Neurobiol. 12:2002;211-216
32. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713
33. Duyckaerts C., Colle M.A., Dessi F., Grignon Y., Piette F., Hauw J.J. The progression of the lesions in Alzheimer-disease - Insights from a prospective clinicopathological study. J. Neural. Trans. Suppl. 53:1998;119-126
34. Esler W.P., Kimberly W.T., Ostaszewski B.L., Diehl T.S., Moore C.L., Tsai J.-Y., Rahmati T., Xia W., Selkoe D.J., Wolfe M.S. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat. Cell Biol. 2:2000;428-434
35. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 262:1989;2551
36. Everall I.P., DeTeresa R., Terry R., Masliah E. Comparison of two quantitative methods for the evaluation of neuronal number in the frontal cortex in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;1202-1206
37. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., Holtzman D.M. Human and murine ApoE markedly alters Abeta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9:2002;305-318
38. Fraser P.E., Nguyen J.T., Inouye H., Surewicz W.K., Selkoe D.J., Podlisny M.B., Kirschner D.A. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid β-protein. Biochemistry. 31:1992;10716-10723
39. Funato H., Enya M., Yoshimura M., Morishima-Kawashima M., Ihara Y. Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am. J. Pathol. 155:1999;23-28
40. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527
41. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4:1998;827-831
42. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Merce Boada, M., Forette, F., Orgogozo, J.-M. (2004). Neuropsychological, CSF, and neuropathological effects of A-Beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurobiol. Aging. 25, S2, 84.
43. Glenner G.G., Wong C.W. Alzheimer's disease. Initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120:1984;885-890
44. Goate A., Chartier-Harlin M.-C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-706
45. Goldgaber D., Lerman M.I., McBridge O.W., Saffiotti V., Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science. 235:1987;877-880
46. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:1997;17-24
47. Haass C., Schlossmacher M., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B., Lieberburg I., Koo E.H., Schenk D., Teplow D., Selkoe D. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325
48. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:1991;383-388
49. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease. progress and problems on the road to therapeutics Science. 297:2002;353-356
50. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Jr. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:1997;119-125
51. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Assembly of Aβ amyloid protofibrils. An in vitro model for a possible early event in Alzheimer's disease Biochemistry. 38:1999;8972-8980
52. Hartley D., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19:1999;8876-8884
53. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. State-specific projections through 2025 of Alzheimer disease prevalence. Neurology. 62:2004;1645
54. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 38:2003;547-554
55. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA. 96:1999;3228-3233
56. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 33:1998;883-889
57. Hsiao K., Chapman P., Nilsen S., Ekman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102
58. Hutton M., Lendon C., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., et al. Association of missense and 5′-splice-site mutations in tau with the inherited FTDP-17. Nature. 393:1998;702-705
59. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 56:1997;965-973. a
60. Irizarry M.C., Soriano F., McNamara M., Page K.J., Schenk D., Games D., Hyman B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17:1997;7053-7059. b
61. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., et al. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982
62. Jarrett J.T., Berger E.P., Lansbury P.T. Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation. Implications for the pathogenesis of Alzheimer's disease Biochemistry. 32:1993;4693-4697
63. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555
64. Kamino K., Orr H.T., Payami H., Wijsman E.M., Alonso E., Pulst S.M., Anderson L., O'dahl S., Nemens E., White J.A., et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am. J. Hum. Genet. 51:1992;998-1014
65. Kang J., Lemaire H.-G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.-H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 325:1987;733-736
66. Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., Matsubara E., Abe K., Ashe K.H., Younkin S.G. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 24:2004;3801-3809
67. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105
68. Kidd M. Alzheimer's disease - An electron microscopical study. Brain. 87:1964;307-320
69. Knopman D.S., Parisi J.E., Salviati A., Floriach-Robert M., Boeve B.F., Ivnik R.J., Smith G.E., Dickson D.W., Johnson K.A., Petersen L.E., et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62:2003;1087-1095
70. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10:2004;719-726
71. Kukull W.A., Bowen J.D. Dementia epidemiology. Med. Clin. North Am. 86:2002;573-590
72. Kuo Y.-M., Emmerling M.R., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., Ball M.J., Roher A.E. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271:1996;4077-4081
73. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:1998;6448-6453
74. Lanz T.A., Carter D.B., Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol. Dis. 13:2003;246-253
75. Larson J., Lynch G., Games D., Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 840:1999;23-35
76. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:2001;1121-1159
77. Lee H.-G., Zhu X., Petersen R.B., Perry G., Smith M.A. Amyloids, aggregates and neuronal inclusions. Good or bad news for neurons? Curr. Med. Chem. Immun. Endoc. Metab. Agents. 3:2003;293-298
78. Lemere C.A., Lopera F., Kosik K.S., Lendon C.L., Ossa J., Saido T.C., Yamaguchi H., Ruiz A., Martinez A., Madrigal L., et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat. Med. 2:1996;1146-1150
79. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., Bots G.T.A.M., Luyendijk W., Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science. 248:1990;1124-1126
80. Levy-Lahad E., Wijsman E.M., Nemens E., Anderson L., Goddard A.B., Weber J.L., Bird T.D., Schellenberg G.D. A familial Alzheimer's disease locus on chromosome 1. Science. 269:1995;970-973
81. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491
82. Li Y.-M., Xu M., Lai M.-T., Huang Q., Castro J.L., DiMuzio-Mower J., Harrison T., Lellis C., Nadin A., Neduvelli J.G., et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 405:2000;689-694
83. Lorenzo A., Yankner B. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA. 91:1994;12243-12247
84. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862
85. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan L., Netzer W.J., Xu H.X., Butko P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. USA. 99:2002;12197-12202
86. Maat-Schieman M.L.C., van Duinen S.G., Haan J., Roos R.A.C. Morphology of cerebral plaque-like lesions in hereditary cerebral hemorrhage with amyloidosis (Dutch). Acta Neuropathol. (Berl). 84:1992;674-679
87. Maat-Schieman M.L.C., Radder C.M., van Duinen S.G., Haan J., Roos R. Hereditary cerebral hemorrhage with amyloidosis (dutch) - a model for congophilic plaque formation without neurofibrillary pathology. Acta Neuropathol. (Berl.). 88:1994;371-378
88. Mandelkow E.M., Stamer K., Vogel R., Thies E., Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging. 24:2003;1079-1085
89. Mann D.M.A. Alzheimer's disease and Down's syndrome. Histopathology. 13:1988;125-137
90. Mann D.M., Yates P.O., Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol. Appl. Neurobiol. 10:1984;185-207
91. Masliah E., Terry R.D., Mallory M. Diffuse plaques do not accentuate synapse loss in Alzheimer disease. Am. J. Pathol. 137:1990;1293-1297
92. Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel D.W. Jr., Morris J.C. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology. 56:2001;127-129
93. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 82:1985;4245-4249
94. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:1999;860-866
95. Mesulam M.M. Neuroplasticity failure in Alzheimer's disease. bridging the gap between plaques and tangles Neuron. 24:1999;521-529
96. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274:1999;6483-6492
97. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985
98. Morishima-Kawashima M., Ihara Y. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry. 37:1998;15247-15253
99. Morris J.C., Rubin E.H. Clinical diagnosis and course of Alzheimer's disease. Psychiatr. Clin. North Am. 14:1991;223-236
100. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice. synaptotoxicity without plaque formation J. Neurosci. 20:2000;4050-4058
101. Neve R.L., Robakis N.K. Alzheimer's disease. A re-examination of the amyloid hypothesis Trends Neurosci. 21:1998;15-19
102. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide. a case report Nat. Med. 2003 9:2003;448-452
103. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4:2001;887-893
104. O'Hare E., Levine A.S., Semotuk M.T., Tierney K.J., Shephard R.A., Grace M.K., Cleary J. Utilization of a novel model of food reinforced behavior involving neuropeptide Y, insulin, 2-deoxy-d-glucose and naloxone. Behav. Pharmacol. 7:1996;742-753
105. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles. intracellular Abeta and synaptic dysfunction Neuron. 39:2003;409-421
106. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.Q., Raber J., Masliah E., Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA. 100:2003;9572-9577
107. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:1991;311-314
108. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43:1998;815-825
109. Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., Butler A.C. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43:1998;380-383
110. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease. allelic variation and receptor interactions Neuron. 11:1993;575-580
111. Richardson R.L., Kim E.M., Shephard R.A., Gardiner T., Cleary J., O'Hare E. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res. 954:2002;1-10
112. Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc. Natl. Acad. Sci. USA. 84:1987;4190-4194
113. Rogaev E.I., Sherrington R., Rogaeva E.A., Levesque G., Ikeda M., Liang Y., Chi H., Lin C., Holamn K., Tsuda T., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 376:1995;775-778
114. Romanelli M.F., Morris J.C., Ashkin K., Coben L.A. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch. Neurol. 47:1990;847-850
115. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472
116. Schauwecker P.E., Steward O. Genetic determinants of susceptibility to excitotoxic cell death. implications for gene targeting approaches Proc. Natl. Acad. Sci. USA. 94:1997;4103-4108
117. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177
118. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870
119. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;9649-9653
120. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron. 6:1991;487-498
121. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer disease. Nature. 375:1995;754-760
122. Skovronsky D.M., Doms R.W., Lee V.M.-Y. Detection of a novel intraneuronal pool of insoluble amyloid β protein that accumulates with time in culture. J. Cell Biol. 141:1998;1031-1039
123. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA. 95:1998;7737-7741
124. Stine W.B. Jr., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278:2003;11612-11622
125. Strittmatter W.J., Weisgraber K.H., Huand D., Dong L.-M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunder A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid β peptide. isoform specific effects and implications for late-onset Alzheimer disease Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102
126. Sturchler-Pierrat C., Abrahamowski D., Duke M., Wiederhold K.-H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA. 94:1997;13287-13292
127. Sze C.I., Troncoso J.C., Kawas C., Mouton P., Price D.L., Martin L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropathol. Exp. Neurol. 56:1997;933-944
128. Tagliavini F., Rossi G., Padovani A., Magoni M., Andora G., Sgarzi M., Bizzi A., Savioardo M., Carella F., Morbin M., et al. A new βpp mutation related to hereditary cerebral hemorrhage. Alz. Rep. Suppl. 2:1999;S28
129. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24:2004;3592-3599
130. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.B., St. George-Hyslop P.H., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., Neve R.L. Amyloid β-protein gene. cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus Science. 235:1987;880-884
131. Terry R.D. The fine structure of neurofibrillary tangles in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 22:1963;629-642
132. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease. synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30:1991;572-580
133. Urbanc B., Cruz L., Le R., Sanders J., Ashe K.H., Duff K., Stanley H.E., Irizarry M.C., Hyman B.T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 99:2002;13990-13995
134. Uylings H.B., de Brabander J.M. Neuronal changes in normal human aging and Alzheimer's disease. Brain Cogn. 49:2002;268-276
135. Van Nostrand W.E., Melchor J.P., Cho H.S., Greenberg S.M., Rebeck G.W. Pathogenic effects of D23N Iowa mutant amyloid beta-protein. J. Biol. Chem. 276:2001;32860-32866
136. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation. reversibility by drugs that enhance cAMP signaling Proc. Natl. Acad. Sci. USA. 99:2002;13217-13221
137. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate J. Biol. Chem. 272:1997;22364-22374
138. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., Teplow D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274:1999;25945-25952
139. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain. Biochemistry. 39:2000;10831-10839
140. Walsh D., Klyubin I., Fadeeva J., William K., Cullen W., Anwyl R., Wolfe M., Rowan M., Selkoe D. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539
141. Walsh D.M., Hartley D.M., Selkoe D.J. The many faces of Aβ Structures and activity Curr. Med. Chem. Immun. Endoc. Metab. Agents. 3:2003;277-291
142. Walsh, D.M., Townsend, T.M., Podlisny, M.B., Shankar, G.M., Fadeeva, J., El Agnaf, O., Hartley, D.M., and Selkoe, D.J. (2004). Certain inhibitors of synthetic Aβ fibrillogenesis block oligomerization of natural Aβ and rescue LTP.
143. Wang J., Dickson D.W., Trojanowski J.Q., Lee V.M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158:1999;328-337
144. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924:2002;133-140
145. Wang Q., Walsh D.M., Rowan M.J., Selkoe D.J., Anwyl R. Block of LTP induction in vitro by cell-derived and synthetic Aβ is mediated via activation of the kinases JNK, Cdk5 and p38 MAPK, and mGluR5. J. Neurosci. 24:2004;6047-6056
146. Watson D.J., Selkoe D.J., Teplow D.B. Effects of the amyloid precursor protein Glu(693) -〉 Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. Biochem. J. 340:1999;703-709
147. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Issazadeh S., Hancock W.W., Selkoe D.J. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:2000;567-579
148. Westphalen R.I., Scott H.L., Dodd P.R. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease. J. Neural Transm. 110:2003;1013-1027
149. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature. 398:1999;513-517
150. Wu C.C., Chawla F., Games D., Rydel R.E., Freedman S., Schenk D., Young W.G., Morrison J.H., Bloom F.E. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice. digital morphometric analyses Proc. Natl. Acad. Sci. USA. 101:2004;7141-7146
151. Yao P.J., Zhu M., Pyun E.I., Brooks A.I., Therianos S., Meyers V.E., Coleman P.D. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol. Dis. 12:2003;97-109
152. Ye C., Walsh D.M., Selkoe D.J., Hartley D.M. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state. N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation Neurosci. Lett. 366:2004;320-325